Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07343960 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
A Phase 1 study of Moderate Hepatic Impairment, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT07343960 is a Phase 1 study of Moderate Hepatic Impairment that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 20 participants, roughly in line with the 21-participant average among 4 other Moderate Hepatic Impairment trials with a reported enrollment target. The trial reports 2 study locations across 2 states.
The verdict
NCT07343960, a Phase 1 study of Moderate Hepatic Impairment, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment and participants with normal hepatic function (as control).
Conditions Studied
Interventions
- DRUG Capivasertib
Study Locations (2)
California
- Research Site - Rialto
Texas
- Research Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-06 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07343960
The ClinicalTrials.gov registry entry for NCT07343960 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 21-participant average among 4 other Moderate Hepatic Impairment trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate Hepatic Impairment appearing as the primary indexed condition, and to 1 intervention - of which Capivasertib is the first listed.
NCT07343960 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT07343960 about?
NCT07343960 is a clinical study titled "A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment". The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment and participants with normal hepatic function (as control).
What is the current status of trial NCT07343960?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-01-06. Estimated completion is 2026-07-31.
What conditions does trial NCT07343960 study?
This clinical trial studies the following conditions: Moderate Hepatic Impairment.
What interventions are being tested in trial NCT07343960?
The interventions under investigation include: Capivasertib (DRUG).
Who is sponsoring clinical trial NCT07343960?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07343960 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate Hepatic Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
RECRUITING · Phase 1
-
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
COMPLETED · Phase 1
-
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
COMPLETED · Phase 1
-
A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.